Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Breast Neoplasms 5Sleep Wake Disorders 1Sleep Disorders, Circadian Rhythm 1Radiodermatitis 1Radiation Injuries 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pain 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Keratosis, Actinic 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Depression 1Delirium 1Brain Neoplasms 1Brain Concussion 1

Interventions

Ipilimumab 106Nivolumab 101pembrolizumab 90aldesleukin 72Cyclophosphamide 46Interleukin-2 45Temozolomide 36Dacarbazine 32trametinib 31dabrafenib 30fludarabine phosphate 29incomplete Freund's adjuvant 27Bevacizumab 26sargramostim 25Vemurafenib 25fludarabine 22binimetinib 21Radiosurgery 21Paclitaxel 20encorafenib 19Carboplatin 19CTLA-4 Antigen 18cobimetinib 16atezolizumab 15Radiotherapy 14Biopsy 14Sorafenib 13MART-1 Antigen 12talimogene laherparepvec 11montanide ISA 51 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Melanoma × Melatonin × Clear all
NCT02190838 2019-11-25

Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma

N.N. Petrov National Medical Research Center of Oncology

Phase 2 Terminated
57 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡